, an antiviral drug discovery company, focused on the development of novel curative treatments for chronic HBV infection, announced that it has completed the initial round
of $3M seed financing led by Torrey Pines
Investment. The funding will advance Chromis' innovative platform of antiviral drugs, including cccDNA inhibitors, entry inhibitors and capsid assembly inhibitors, for the treatment of the Hepatitis B virus (HBV).